<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216138</url>
  </required_header>
  <id_info>
    <org_study_id>HOG HN02-40</org_study_id>
    <nct_id>NCT00216138</nct_id>
  </id_info>
  <brief_title>Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head &amp; Neck</brief_title>
  <official_title>A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent progress in treatment of recurrent/metastatic SCCHN has been made with the&#xD;
      introduction of the taxanes. Docetaxel as a single agent has a response rate of 22-42% and&#xD;
      17% in patients with recurrent disease. Capecitabine is an oral fluoropyrimidine prodrug that&#xD;
      is converted into 5-FU. Previous studies have shown that the capecitabine/docetaxel&#xD;
      combination has a synergistic inhibition of tumor growth, resulting in significantly superior&#xD;
      efficacy in time to disease progression (TTP), overall survival, median survival and&#xD;
      objective tumor response rate compared to docetaxel alone.&#xD;
&#xD;
      This trial will investigate the efficacy the combination of docetaxel and capecitabine in&#xD;
      treating patients with recurrent/metastatic SCCHN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
        -  Dexamethasone and antiemetic premedication1.&#xD;
&#xD;
        -  Docetaxel: 60 mg/m2 for a 60 minute infusion day 1 of each cycle&#xD;
&#xD;
        -  Capecitabine: 825 mg/m2 po BID Days 1-14&#xD;
&#xD;
      Repeat every 21 days until tumor progression or toxicity that requires discontinuation of&#xD;
      therapy&#xD;
&#xD;
      Performance status: ECOG performance status 0 or 1&#xD;
&#xD;
      Life expectancy: At least 3 months&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  ANC of &gt; 1,500/mm3&#xD;
&#xD;
        -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
        -  Hemoglobin &gt; 8 gm/dl&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Total Bilirubin Â£ ULN&#xD;
&#xD;
        -  Albumin &gt; 3&#xD;
&#xD;
        -  Maximum Alk Phos &gt; 2.5 x &lt; 5 x ULN&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Creatinine clearance of &gt; 50 ml/ min (by Cockcroft-Gault)&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  No decompensated congestive heart failure or active angina.&#xD;
&#xD;
        -  Clinically significant cardiac disease not well controlled with medication (eg.&#xD;
           congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias)&#xD;
           or myocardial infarction in the past 12 months is not allowed.&#xD;
&#xD;
      Pulmonary:&#xD;
&#xD;
        -  Not specified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis results did not meet criteria for second stage of trial&#xD;
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To assess response rate in a group of patients receiving combination therapy with docetaxel and capecitabine</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess toxicity of the combination</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether the status of calpain, calpain activation,(EGFR) expression, Cox-2 expression, TS, TP, DPD, and/or CYP3A4/CYP3A5 will predict treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and safety analyses on special sub-cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the progression free survival and overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess change in analgesic usage with this protocol therapy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 825 mg/m2 po bid, days 1-14</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premedication</intervention_name>
    <description>Dexamethasone and antiemetic premedication</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head&#xD;
             and neck.&#xD;
&#xD;
          -  Recurrent/metastatic disease not amenable to surgery or salvage chemoradiation.&#xD;
&#xD;
          -  Unidimensional measurable disease according to the RECIST&#xD;
&#xD;
          -  In-field recurrence, within a prior radiation field only, distant metastatic disease&#xD;
&#xD;
          -  Both in-field and metastatic sites of disease will require evaluation by a Radiation&#xD;
             Oncologist to consider local radiation therapy first and will be eligible for possible&#xD;
             enrollment one month after completion of the radiation therapy.&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Patients may have received prior chemotherapy as part of chemoradiation or induction&#xD;
             chemotherapy for initial treatment of disease confined to the head and neck region -&#xD;
             Patients must have fully recovered from any prior radiation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have relapsed &lt; 6 months after completing a combined modality curative&#xD;
             treatment that included a fluoropyrimidine or taxanes&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  No major neurological disease, including stroke&#xD;
&#xD;
          -  No prior chemotherapy regimen for recurrent/metastatic disease&#xD;
&#xD;
          -  No prior history of capecitabine usage&#xD;
&#xD;
          -  No prior history of docetaxel usage except in the induction setting for head and neck&#xD;
             cancer which has been completed for greater than 6 months prior to beginning protocol&#xD;
             therapy&#xD;
&#xD;
          -  No past hypersensitivity to taxanes or 5 FU&#xD;
&#xD;
          -  No hypersensitivity to docetaxel or other drugs formulated with polysorbate 80&#xD;
&#xD;
          -  No current use of warfarin&#xD;
&#xD;
          -  Patients must not be receiving ketoconazole, midazolam, erythromycin, orphenadrine,&#xD;
             troleandomycin, cyclosporine or antiepileptics&#xD;
&#xD;
          -  Patients must not be treated with any of the following on protocol therapy or within&#xD;
             28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine,&#xD;
             allopurinol&#xD;
&#xD;
          -  Patients must have fully recovered from any prior surgery&#xD;
&#xD;
          -  No known HIV seropositivity.&#xD;
&#xD;
          -  No serious uncontrolled medical condition, uncontrolled peptic ulcer disease or&#xD;
             malabsorption syndrome&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Patients with a percutaneous gastrostomy (PEG) must be able take medications by tube.&#xD;
&#xD;
          -  No daily consumption of alcohol&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No prior history of malignancy in the last 5 years, excluding in situ carcinoma of the&#xD;
             cervix or adequately treated basal or squamous cell carcinoma of the skin or Gleason&#xD;
             Grade &lt; VII organ confined prostate cancer.&#xD;
&#xD;
          -  No current breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Potter, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen Health System</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46527</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Cancer Center (MCGOP)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care, Inc., P.C.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hematology-Oncology of S Michigan</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org/</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>David Potter, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

